Grail cancer test gets lukewarm backing from FDA adcomm
FDA expert advisors voted in favour of Grail's Galleri blood test for detecting multiple cancers, but some expressed misgivings about its efficacy.
AI specialists Enveda and Basecamp rake in the cash
AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
Roche, Viking, and Syntis showcase obesity drug candidates
A flurry of clinical readouts for new weight-loss therapies has seen Roche, Viking, and Syntis all showing off new drug candidates.
Roche's IgAN hopeful sefaxersen passes phase 3 test
Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.
Amgen's Horizon buyout delivers Sjögren's disease win
Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Six Questions Shaping the Future of Health Innovation
The DIA-MHRA Global Summit explores six questions shaping the next decade of health innovation.
PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...
Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027
PMi Awards 2026 – The Winners and Highlights
Avalere Health is the night’s most awarded agency - Novo Nordisk, Roche, and The Urology Foundation top the client leaderboard
RNA-Targeted Small Molecules: From Discovery to Clinic
Leading pharma, biotech and academic experts discuss the future of RNA therapeutics.
Novel CNS Biomarkers Summit Europe
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation